Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Pulmonology · Severe Eosinophilic Asthma

Do Fasenra or Nucala Protect Against Wildfire Smoke?

At a Glance

Fasenra and Nucala lower baseline lung inflammation, making severe asthma less reactive to wildfire smoke. However, they cannot block direct irritation or PM2.5 particle damage. You must still use HEPA filters, wear N95 masks, and follow your asthma action plan when air quality is poor.

If you have severe eosinophilic asthma (SEA), taking an anti-IL-5 biologic like Fasenra (benralizumab) or Nucala (mepolizumab) can provide a layer of protection against the effects of wildfire smoke, but it does not make your lungs immune to smoke damage. Studies show that patients with severe asthma who are on biologic therapies have a reduced risk of experiencing persistent asthma symptoms following intense smoke exposure compared to those who are not on these medications [1][2].

By keeping your baseline asthma well-controlled and reducing underlying inflammation, these medications make your airways less reactive to environmental triggers [3][4]. However, wildfire smoke contains fine particulate matter (PM2.5) that triggers multiple types of lung irritation, some of which are not blocked by your biologic [5][6].

How Your Biologic Helps During Smoke Events

Fasenra and Nucala work by targeting and depleting eosinophils—a specific type of white blood cell that causes swelling and inflammation in your airways [7][8]. When your eosinophil levels are kept low by these medications:

  • Lower Baseline Inflammation: Your lungs are calmer day-to-day. When smoke enters your airways, it is hitting lungs that have lower airway hyperresponsiveness (meaning they are less “twitchy”), so the smoke is less likely to trigger an immediate, severe attack [3][9].
  • Fewer Severe Exacerbations: These medications are proven to significantly reduce the overall frequency of severe asthma attacks [10][11].
  • Quicker Recovery: Because your baseline inflammation is managed, research suggests you may recover faster and have fewer lingering symptoms after the smoke clears [1].

Why You Still Need to Protect Yourself

While your biologic protects you against eosinophil-driven inflammation, wildfire smoke is a complex mix of toxic gases and fine particles (PM2.5). When you breathe in wildfire smoke, it triggers different types of reactions in your lungs that Fasenra and Nucala do not treat:

  • Direct Irritation and Toxicity: The physical particles in smoke act like sandpaper in your airways, causing direct physical irritation, general inflammation, and oxidative stress (a type of chemical damage to your lung cells) [6][12].
  • Neutrophilic Inflammation: Smoke often causes your body to deploy a different type of immune cell called neutrophils to clean up the ash and debris [13]. Because your biologic only targets eosinophils, it cannot stop this neutrophil-driven inflammation.
  • Increased Infection Risk: Heavy smoke exposure can impair your immune system’s ability to fight off bacteria and viruses, leaving you vulnerable to secondary respiratory infections [13].

Action Steps During Wildfire Season

Even if your asthma feels completely controlled on Fasenra or Nucala, you must treat wildfire smoke as a serious threat.

  • Track Air Quality Carefully: Monitor local Air Quality Index (AQI) forecasts, paying special attention to PM2.5 levels. Because you have severe asthma, you should consider staying indoors when the AQI reaches 100 (“Unhealthy for Sensitive Groups”), or even sooner if you notice symptoms.
  • Create a Clean Air Sanctuary: Keep windows closed and use HEPA air purifiers to keep indoor air clean. If you have a central HVAC system, check if you can upgrade to MERV-13 filters, which are highly effective at trapping PM2.5 particles.
  • Wear a High-Quality, Tight-Fitting Mask: If you must go outside, wear an N95 or KN95 respirator mask. The mask must fit tightly against your face without gaps—a loose mask will let fine smoke particles slip right through.
  • Review Your Asthma Action Plan: Before smoke season begins, review your written asthma action plan with your doctor. Know exactly what steps to take if the smoke triggers an attack.
  • Know When to Seek Emergency Care: Keep your rescue inhaler (albuterol) handy. If you use your rescue medication and it does not provide relief, or if you experience rapidly worsening shortness of breath, severe chest tightness, or trouble speaking in full sentences, follow your action plan and seek immediate emergency medical attention.

Common questions in this guide

Do Fasenra or Nucala completely protect my asthma from wildfire smoke?
No. While these medications reduce baseline inflammation and make your lungs less reactive, they do not block the direct physical irritation or non-eosinophilic inflammation caused by fine smoke particles (PM2.5).
Should I change my daily asthma inhaler dose during a wildfire event?
You should never adjust your maintenance inhaler dose without consulting your doctor. Review your asthma action plan with your healthcare provider before smoke season to know exactly what steps to take if air quality reaches dangerous levels.
Can wildfire smoke cause a different type of asthma attack?
Yes. Wildfire smoke can trigger neutrophilic inflammation, which involves a different type of immune cell than the eosinophils targeted by Fasenra and Nucala. This means you can still experience a flare-up even if your biologic is working perfectly.
What type of mask works best for asthma during wildfires?
You should wear a tight-fitting N95 or KN95 respirator mask when going outside. Loose-fitting masks, cloth masks, and standard surgical masks will not filter out the dangerous fine particulate matter found in wildfire smoke.
When should I go to the emergency room for asthma during a smoke event?
Seek immediate emergency care if your rescue inhaler does not provide relief, or if you experience rapidly worsening shortness of breath, severe chest tightness, or trouble speaking in full sentences.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my history with eosinophilic asthma, should I adjust my daily maintenance inhaler dose when the air quality index reaches dangerous levels?
  2. 2.If I experience an exacerbation during a wildfire event despite being on my biologic, what is the action plan?
  3. 3.Could the smoke exposure trigger a different type of inflammation (like neutrophilic) that would require a short course of oral steroids or a different treatment approach?
  4. 4.Are there additional tests, like a blood test for eosinophils, we should do after a period of heavy smoke exposure to ensure my biologic is still working effectively?
  5. 5.If my rescue inhaler isn't working during a smoke event, at what exact point should I go to urgent care versus the emergency room?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (13)
  1. 1

    Effect of Acute PM2.5 Exposure on Lung Function in Children: A Systematic Review and Meta-Analysis.

    Zhang Y, Guo Z, Zhang W, et al.

    Journal of asthma and allergy 2023; (16()):529-540 doi:10.2147/JAA.S405929.

    PMID: 37193111
  2. 2

    'Breathing Fire': Impact of Prolonged Bushfire Smoke Exposure in People with Severe Asthma.

    Beyene T, Harvey ES, Van Buskirk J, et al.

    International journal of environmental research and public health 2022; (19(12)) doi:10.3390/ijerph19127419.

    PMID: 35742668
  3. 3

    Eosinophil depletion with benralizumab is associated with attenuated mannitol airway hyperresponsiveness in severe uncontrolled eosinophilic asthma.

    Chan R, RuiWen Kuo C, Jabbal S, Lipworth BJ

    The Journal of allergy and clinical immunology 2023; (151(3)):700-705.e10 doi:10.1016/j.jaci.2022.10.028.

    PMID: 36400178
  4. 4

    Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.

    Akenroye A, Lassiter G, Jackson JW, et al.

    The Journal of allergy and clinical immunology 2022; (150(5)):1097-1105.e12 doi:10.1016/j.jaci.2022.05.024.

    PMID: 35772597
  5. 5

    Activation of Notch1-GATA3 pathway in asthma bronchial epithelial cells induced by acute PM2.5 exposure and the potential protective role of microRNA-139-5p.

    Huang J, Hu Y, Wang Y, Jin Z

    The Journal of asthma : official journal of the Association for the Care of Asthma 2024; (61(9)):959-969 doi:10.1080/02770903.2024.2316711.

    PMID: 38346176
  6. 6

    Wildfire Smoke: Health Effects, Mechanisms, and Mitigation.

    Lei Y, Lei TH, Lu C, et al.

    Environmental science & technology 2024; (58(48)):21097-21119 doi:10.1021/acs.est.4c06653.

    PMID: 39516728
  7. 7

    The Comparative Effectiveness of Mepolizumab and Benralizumab in the Treatment of Eosinophilic Asthma.

    Niemiec-Górska A, Branicka O, Olszewska P, et al.

    Advances in respiratory medicine 2025; (93(4)) doi:10.3390/arm93040021.

    PMID: 40862698
  8. 8

    Monoclonal antibodies in severe asthma: outcomes from real-world data.

    Del-Barrio-Buesa S, Narrillos-Moraza Á, García-de-Pedro J, et al.

    Frontiers in medicine 2025; (12()):1635688 doi:10.3389/fmed.2025.1635688.

    PMID: 40873794
  9. 9

    Targeting IL-5 pathway against airway hyperresponsiveness: A comparison between benralizumab and mepolizumab.

    Calzetta L, Ritondo BL, Matera MG, et al.

    British journal of pharmacology 2020; (177(20)):4750-4765 doi:10.1111/bph.15240.

    PMID: 32857420
  10. 10

    Treatment of allergic bronchopulmonary aspergillosis with biologics.

    Asano K, Tomomatsu K, Okada N, et al.

    Chinese medical journal pulmonary and critical care medicine 2025; (3(1)):6-11 doi:10.1016/j.pccm.2024.11.005.

    PMID: 40226607
  11. 11

    Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.

    Agache I, Beltran J, Akdis C, et al.

    Allergy 2020; (75(5)):1023-1042 doi:10.1111/all.14221.

    PMID: 32034960
  12. 12

    "Air That Once Was Breath" Part 1: Wildfire-Smoke-Induced Mechanisms of Airway Inflammation - "Climate Change, Allergy and Immunology" Special IAAI Article Collection: Collegium Internationale Allergologicum Update 2023.

    Bowman WS, Schmidt RJ, Sanghar GK, et al.

    International archives of allergy and immunology 2024; (185(6)):600-616 doi:10.1159/000536578.

    PMID: 38452750
  13. 13

    Fine particulate matter 2.5 induces susceptibility to Pseudomonas aeruginosa infection via expansion of PD-L1high neutrophils in mice.

    Luo L, Jiang M, Xiong Y, et al.

    Respiratory research 2024; (25(1)):90 doi:10.1186/s12931-023-02640-x.

    PMID: 38355515

This page provides general educational information about managing severe eosinophilic asthma during wildfire events. It does not replace professional medical advice, and you should always consult your pulmonologist or allergist to establish your personal asthma action plan.

Get notified when new evidence is published on Severe Refractory Eosinophilic Asthma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.